T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016', provides in depth analysis on T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted pipeline therapeutics. 

The report provides comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
- The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects 
- The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Overview 6
Therapeutics Development 7
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Products under Development by Stage of Development 7
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Products under Development by Therapy Area 8
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Products under Development by Indication 9
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Products under Development by Companies 13
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development 21
Atox Bio Ltd. 21
Bristol-Myers Squibb Company 22
OSE Immunotherapeutics 23
TheraMAB LLC 24
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles 25
AB-103 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
FR-104 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
lulizumab pegol - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
MF-280 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
TAB-08 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Projects 35
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Featured News & Press Releases 36
Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections 36
Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria) 36
Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control 37
Apr 15, 2015: Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104 38
Feb 12, 2015: Two major scientific articles validate Effimune's drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system 38
Dec 25, 2014: TheraMAB presents new clinical data on theralizumab (TAB08) at Nature Biotechnology 39
Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority 40
Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections 41
Jan 14, 2014: TheraMAB announces initiation of Phase II clinical trial of mAb TABO8 for the treatment of Rheumatoid Arthritis 41
Apr 09, 2013: Atox Bio Publishes Data Demonstrating Broad Therapeutic Effect Of Flagship Product In Treating Flesh Eating Bacteria 42
Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial 43
Sep 10, 2012: Atox Bio's AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections 44
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 44
Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections 45
May 12, 2011: Atox Bio Completes Phase I clinical study Of AB103 For Severe Bacterial Infections And Sepsis 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Atox Bio Ltd., H2 2016 21
Pipeline by Bristol-Myers Squibb Company, H2 2016 22
Pipeline by OSE Immunotherapeutics, H2 2016 23
Pipeline by TheraMAB LLC, H2 2016 24
Dormant Projects, H2 2016 35